Latest News and Press Releases

ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced the appointment of Catherine Coffey Ross as Vice President, Medical Affairs. Ms. Coffey Ross’...

Data to be presented at the EASL Digital International Liver Congress™ 2021 Two poster presentations and supporting slides are available at...

HBV-TAG: Presentation of in vitro antiviral activity and Phase 1a healthy volunteer data demonstrating the safety, tolerability, and favorable pharmacokinetics of multiple ascending doses of ATI-2173 ...

Responsible for managing clinical development and the regulatory processes for ATI-2173, an ASPIN, which is in development as part of a potential curative regimen for chronic hepatitis B infection ...

SAVE 1 to evaluate ATI-2173 in combination with tenofovir (TDF) vs. TDF plus placebo SAVE 1 to include cohort of Hepatitis Delta Virus (HDV) co-infected subjects to assess ATI-2173 activity against...

Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling...

ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced the appointment of seasoned financial executive, Tamra J. Adams, as the Company’s chief financial...

Former biopharmaceutical executive has been at the forefront of developing treatments for infectious diseases of the liver including HBV and HCV ATLANTA, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Antios...

Study results expected to be presented in mid-2021 ATLANTA, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced that it has completed the Phase 1b clinical trial...

Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential backbone of a curative regimen...